Back

Exercise dose and threshold for adverse outcome in arrhythmogenic cardiomyopathy

29 August 2017 (09:33 - 09:42)
Organised by:
Congress Presentation Part of: Cardiomyopathies: new insights Cardiomyopathies ESC Premium Access ESC Congress 2017

About the speaker

Photo
Doctor Oyvind H Lie

Oslo University Hospital Rikshospitalet, Oslo (Norway)

8 More presentations in this session

Presentation thumbnail
Immune-mediated myocardial inflammation in Fabry Disease cardiomyopathy
Doctor A. Frustaci (Rome, IT)
Abstract
Presentation thumbnail
Takotsubo cardiomyopathy complicated by cardiogenic shock. Insights from the nationwide RETAKO Registry
Doctor M. Almendro (Seville, ES)
Abstract Slides Video
Presentation thumbnail
Discordance between the criteria for ICD implantation in the primary prevention of sudden death among patients with hypertrophic cardiomyopathy
Doctor P. Freitas (Carnaxide, PT)
Abstract Slides Video
Presentation thumbnail
Cardiac transplantation in hypertrophic cardiomyopathy in the united states: 2003-2011.
Doctor J. Shirani (Bethlehem, US)
Abstract Slides Video
Presentation thumbnail
Cardiac sarcoidosis may meet the diagnostic criteria for arrhythmogenic right ventricular cardiomyopathy
Doctor P. Simonen (Helsinki, FI)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiomyopathies: new insights

The Event

Event poster

ESC Congress 2017

29 August 2017 09:33 CET
You may be interested in
thumbnail
Congress Presentation
Exercise prescription in patients with cardiomyopathies
4 April 2025
thumbnail
Congress Presentation
Viviane Conraads Award Lecture
15 April 2023
thumbnail
Congress Presentation
Threshold values by electrocardiogram and echocardiography indicating transition to an arrhythmic phenotype in cardiac laminopathies: a primary prevention cohort study
3 April 2022
thumbnail
Congress Presentation
The influence of exercise modality and intensity on ventricular arrhythmia burden and perception of effort in patients with Arrhythmogenic Right Ventricular Cardiomyopathy with plakophilin-2 variants
31 March 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources